Business

The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of OPK, ABBV, MGTI, HAS and CPB

The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of OPK, ABBV, MGTI, HAS and CPB.

articleMgt Capital Investments, Inc.November 11, 20184/company/mgt-capital-investments-inc/news/the-klein-law-firm-reminds-investors-of-class-actions-on-behalf-of-shareholders-of-opk-abbv-mgti-has-and-cpb
The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of OPK, ABBV, MGTI, HAS and CPB

About this update from Mgt Capital Investments, Inc.

[{"type":"text","content":"\nNEW YORK, Nov. 11, 2018 (GLOBE NEWSWIRE) -- The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff. \n OPKO Health Inc. (NASDAQ: OPK) Class Period: September 26, 2013 to September 7, 2018 Lead Plaintiff Deadline: November 13, 2018 During the class period, OPKO Health Inc. allegedly made materially false and/or misleading statements and/or failed to disclose that: (1) OPKO and its Chairman and Chief Executive Officer, Phillip Frost, were engaged in a pump-and-dump scheme with several other individuals and companies in their investments in several penny stocks; (2) this illicit scheme would result in governmental scrutiny including from the SEC; and (3) as a result, defendants’ statements about OPKO’s business, operations and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times. Get additional information about the OPK lawsuit: http://www.kleinstocklaw.com/pslra-1/opko-health-inc-loss-submission-form?wire=3 AbbVie Inc. (NYSE: ABBV) Class Period: October 25, 2013 to September 18, 2018 Lead Plaintiff Deadline: November 20, 2018 The lawsuit alleges AbbVie Inc. made materially false and/or misleading statements and/or failed to disclose during the class period that: (1) AbbVie’s strategy to increase the sales growth of its blockbuster drug, HUMIRA, relied in part upon illegal kickbacks and unlawful sales and marketing tactics; (2) such practices would foreseeably lead to heightened scrutiny by State governments and agencies; and (3) as a result, Defendants’ public statements were materially false and misleading at all relevant times. Get additional information about the ABBV lawsuit: http://www.kleinstocklaw.com/pslra-1/abbvie-inc-loss-submission-form?wire=3 MGT Capital Investments Inc. (OTCMKTS: MGTI) Class Period: October 9, 2015 to September 7, 2018 Lead Plaintiff Deadline: November 27, 2018 The lawsuit alleges that MGT Capital Investments Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) Defendants were engaged in an illegal pump-and-dump scheme to artificially inflate MGT Capital’s stock price; (2) the \"Scheme D...

More updates from Mgt Capital Investments, Inc.